Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
Rheumatology (Oxford)
; 47(3): 339-44, 2008 Mar.
Article
em En
| MEDLINE
| ID: mdl-18238789
ABSTRACT
OBJECTIVE:
To evaluate the efficacy of adalimumab in juvenile idiopathic arthritis (JIA)-associated uveitis.METHODS:
Retrospective observational study of 20 patients with JIA and chronic uveitis on adalimumab treatment. The ocular inflammation and improvement was assessed according to the Standardization of Uveitis Nomenclature criteria.RESULTS:
At the initiation of adalimumab, the mean age of patients was 13.4 yrs and the mean duration of uveitis 8.7 yrs. Seventeen (85%) patients had polyarticular JIA and 19 (95%) had previously been on anti-TNF treatment. The mean duration of adalimumab therapy was 18.7 months. Of the 20 patients, 7 (35%) showed improved activity, 1 (5%) worsening activity and in 12 (60%) no change was observed in the activity of uveitis. Those with improved activity were younger and had shorter disease duration. The mean number of flares/yr decreased from 1.9 to 1.4 during adalimumab treatment. Serious adverse events or side-effects were not observed. Seven patients discontinued adalimumab during the follow-up six because of inefficacy and one because of inactive uveitis.CONCLUSION:
Adalimumab is a potential treatment option in JIA-associated uveitis, even in patients non-responsive to previous other anti-TNF therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Juvenil
/
Uveíte Anterior
/
Anticorpos Monoclonais
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rheumatology (Oxford)
Ano de publicação:
2008
Tipo de documento:
Article